Novavax, Inc.
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
Granted 483.1K
Granted 135.5K
Granted 189.8K
Granted 125.3K
Granted 175.5K · Sold 45.0K
Granted 39.8K · Sold 25.0K
Granted 41.3K
Granted 79.4K · Sold 61.2K
Granted 16.4K · Sold 41.3K
Granted 47.7K
Granted 47.4K
Granted 44.5K
Granted 39.8K · Sold 4.2K
Granted 118.9K · Sold 91.8K
Granted 110.6K · Bought 6.0K · Sold 97.4K
Granted 68.9K · Sold 45.0K
Granted 14.3K
Granted 700
Granted 9.5K
Granted 7.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Jacobs John CPresident and CEO, Director · 10 transactions | — | 225.7K | 483.1K | — | — |
| O'Hara ElaineEVP, Chief Strategy Officer · 8 transactions | — | 157.1K | 135.5K | — | — |
| Kelly James PatrickEVP, CFO and Treasurer · 22 transactions | — | 130.6K | 189.8K | — | — |
| Casey Mark JEVP, Chief Legal Officer · 8 transactions | — | 101.4K | 125.3K | — | — |
| Trizzino JohnPresident and COO · 108 transactions | +11322.7% | 82.0Kas of Mar 2025 | 175.5K | — | 45.0K |
| Mott David MDirector · 10 transactions | +22.8% | 79.8K | 39.8K | — | 25.0K |
| Douglas RichardDirector · 6 transactions | +129.2% | 73.2K | 41.3K | — | — |
| Dubovsky FilipPresident, R&D · 18 transactions | — | 66.6Kas of Jun 2024 | 79.4K | — | 61.2K |
| Young James FDirector · 13 transactions | -31.1% | 51.8Kas of Dec 2024 | 16.4K | — | 41.3K |
| Alton Gregg HDirector · 9 transactions | — | 47.7K | 47.7K | — | — |
| Rodgers Richard JDirector · 6 transactions | — | 47.4K | 47.4K | — | — |
| McGlynn Margaret GDirector · 9 transactions | — | 44.5K | 44.5K | — | — |
| King Rachel K.Director · 6 transactions | +605.1% | 44.1K | 39.8K | — | 4.2K |
| Erck Stanley CPresident and CEO, Director · 45 transactions | +72.4% | 36.5Kas of Dec 2022 | 118.9K | — | 91.8K |
| Glenn Gregory MPresident, R&D · 216 transactions | +125.6% | 18.3Kas of Mar 2023 | 110.6K | 6.0K | 97.4K |
| Herrmann John A IIIEVP, Chief Legal Officer · 106 transactions | +405.5% | 17.3Kas of Dec 2023 | 68.9K | — | 45.0K |
| Draghia-Akli RuxandraSection 16 · 2 transactions | — | 14.3K | 14.3K | — | — |
| McManus Michael A JrDirector · 1 transaction | +7.4% | 10.1Kas of Jun 2022 | 700 | — | — |
| Newton Charles W.Director · 1 transaction | — | 9.5K | 9.5K | — | — |
| Shiver John W.Director · 1 transaction | — | 7.9K | 7.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -404.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.